Experimental local administration of CDDP to in vitro models of gynecological malignant tumors transplanted into nude mice (compared with medroxyprogesterone acetate orally administered).
Experimental local administration of CDDP to in vitro models of gynecological malignant tumors transplanted into nude mice (compared with medroxyprogesterone acetate orally administered).
复制标题
顺铂局部给药裸鼠体外妇科恶性肿瘤模型实验（与口服醋酸甲羟孕酮比较）。
DOI：
--
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
T. Mori
中科院分区：
文献类型：
--
作者：
I. Tateyama;K. Hashii;S. Natsuyama;T. Kanto;T. Tominaga;N. Kamitani;T. Mori
为了开发顺铂的新给药方法，用作者建立的两种妇科恶性肿瘤细胞系制备了体外模型，并进行了顺铂局部注射的基础实验。在荷瘤裸鼠中局部注射CDDP的实验中，试验药物表现出优异的肿瘤消退效果和对肿瘤生长的抑制作用。在组织病理学检查中，观察到肿瘤细胞的特异性坏死。经证实，这是一种高度安全的方法，因为未观察到可归因于CDDP局部给药的组织分离、溃疡或出血性病变。在本研究中，还使用了口服醋酸甲羟孕酮治疗。然而，在本研究中使用的剂量下，未观察到对肿瘤生长的抑制作用或醋酸甲羟孕酮与CDDP之间的协同作用。局部注射是一种优良的药效学方法，其允许将游离铂注射到肿瘤本身或肿瘤与正常组织之间的边界区域中，而不会损失药物，并且其被认为是一种安全有效的局部给药模式。动脉内注射这种药物单独或与OK-432也可以使用，即使需要进一步的研究来确定最佳剂量和减少副作用。目前，正在收集没有其他治疗方法的晚期癌症患者的数据。在不久的将来，这种给药方法有望用于恶性肿瘤的临床治疗，无论是早期肿瘤还是进行性癌症。
In order to develop a new method of administration for CDDP, in vitro models of malignant tumors in the field of gynecology were prepared using two cell lines maintained by the authors, and fundamental experiments on the topical injection of CDDP were carried out. In experimental topical injection of CDDP in tumor-bearing nude mice, the test drug demonstrated an excellent tumor regression effect and an inhibitory effect on tumor growth. In the histopathologic examinations, specific necrosis of tumor cells was observed. It was confirmed that this is a highly safe method, as tissue separation, ulceration, or hemorrhagic lesions attributable to the local administration of CDDP were not observed. In the present study, treatment with oral medroxyprogesterone acetate was also used. At the doses used in this study, however, no inhibitory effect on tumor growth or synergism between medroxyprogesterone acetate and CDDP was observed. Topical injection is an excellent pharmacodynamic method that permits the injection of free platin into the tumor itself or in the boundary area between the tumor and normal tissues, with no loss of the drug, and it is considered a safe and effective mode of local administration. Intra-arterial injection of this drug alone or in conjunction with OK-432 can also be used, even though further studies will be required to determine the optimum dosage and reduce side effects. At present, data are being collected on terminal cancer patients for whom no other therapy is available. In the near future this method of administration is expected to be utilized in the clinical treatment of malignant tumors, be it early tumor or progressive cancer.